242 related articles for article (PubMed ID: 1331485)
1. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD
J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485
[TBL] [Abstract][Full Text] [Related]
2. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Eckardt JR; Burris HA; Kuhn JG; Bissery MC; Klink-Alakl M; Clark GM; Von Hoff DD
J Natl Cancer Inst; 1994 Jan; 86(1):30-3. PubMed ID: 8271279
[TBL] [Abstract][Full Text] [Related]
3. Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.
Cobb PW; Degen DR; Clark GM; Chen SF; Kuhn JG; Gross JL; Kirshenbaum MR; Sun JH; Burris HA; Von Hoff DD
J Natl Cancer Inst; 1994 Oct; 86(19):1462-5. PubMed ID: 8089865
[TBL] [Abstract][Full Text] [Related]
4. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Shimada Y; Rothenberg M; Hilsenbeck SG; Burris HA; Degen D; Von Hoff DD
Anticancer Drugs; 1994 Apr; 5(2):202-6. PubMed ID: 8049503
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
Mattern MR; Hofmann GA; McCabe FL; Johnson RK
Cancer Res; 1991 Nov; 51(21):5813-6. PubMed ID: 1657371
[TBL] [Abstract][Full Text] [Related]
7. Activity of temozolomide against human tumor colony-forming units.
Raymond E; Izbicka E; Soda H; Gerson SL; Dugan M; Von Hoff DD
Clin Cancer Res; 1997 Oct; 3(10):1769-74. PubMed ID: 9815562
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and phase I trials of topoisomerase I inhibitors.
Von Hoff DD; Burris HA; Eckardt J; Rothenberg M; Fields SM; Chen SF; Kuhn JG
Cancer Chemother Pharmacol; 1994; 34 Suppl():S41-5. PubMed ID: 8070026
[TBL] [Abstract][Full Text] [Related]
11. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
12. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Lamond JP; Wang M; Kinsella TJ; Boothman DA
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):361-8. PubMed ID: 8892461
[TBL] [Abstract][Full Text] [Related]
13. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
14. Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
Lawrence RA; Izbicka E; De Jager RL; Tohgo A; Clark GM; Weitman SD; Rowinsky EK; Von Hoff DD
Anticancer Drugs; 1999 Aug; 10(7):655-61. PubMed ID: 10507315
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
[TBL] [Abstract][Full Text] [Related]
16. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro.
Erickson-Miller CL; May RD; Tomaszewski J; Osborn B; Murphy MJ; Page JG; Parchment RE
Cancer Chemother Pharmacol; 1997; 39(5):467-72. PubMed ID: 9054963
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Keshelava N; Groshen S; Reynolds CP
Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
[TBL] [Abstract][Full Text] [Related]
19. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
20. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Teicher BA; Holden SA; Khandakar V; Herman TS
J Cancer Res Clin Oncol; 1993; 119(11):645-51. PubMed ID: 8394365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
